Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Yuqin Song(Peking University), Jun Zhu(Peking University), Bing Xu(First Affiliated Hospital of Xiamen University), Chunyan Ji(Nanjing University of Chinese Medicine), Zunmin Zhu(Zhengzhou University), Haiyan Yang(Zhejiang Cancer Hospital), Ying Cheng(Jilin Province Tumor Hospital), Renbin Zhao(Kunming University of Science and Technology), Zhengguang Lu(Florida State University), Yu Hu(Wuhan Union Hospital), Jianda Hu(Fujian Medical University), Junning Cao(Fudan University Shanghai Cancer Center), Sujun Gao(Jilin University), Hongmei Jing(Peking University), Yongping Song(First Affiliated Hospital of Zhengzhou University), Xin Wang(Shandong Provincial Hospital), Mingzhi Zhang(Chinese Academy of Sciences), Bin Zhang(Ningbo University), Ting Liu(Chinese PLA General Hospital), Lihong Liu(Hebei Medical University), Yan Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Xu(Jiangsu Province Hospital), Kaiyang Ding(Anhui Provincial Hospital), Huilai Zhang(Shanxi Medical University), Zhixin Xu, Zhiming Li(Anhui Medical University)
Blood
November 13, 2019
10.1182/blood-2019-126305
Cited by 27

Related Papers

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Targeting the Wnt/β-catenin signaling pathway in cancer
|Journal of Hematology & Oncology|2020|1.4k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k